InvestorsHub Logo
Followers 14
Posts 2860
Boards Moderated 0
Alias Born 12/23/2014

Re: mrholty post# 2250

Wednesday, 10/24/2018 6:23:04 AM

Wednesday, October 24, 2018 6:23:04 AM

Post# of 2463
no surprises - met expectations. The new management is executing and will continue to grow the company. The mention of "higher regulatory expenditures" means that new products will coming. "clinical trial activity" was mentioned as it was in the previous quarter. The press release reminded me that the company's balance sheet has no debt and a growing cash position.